Physician profile
Siew Jackson
NPI 1174212336
$1,239.55
in general payments reported to CMS, 2019-2025
21 companies · $958 in 2025
The $958 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $282 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $155.53 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Stemline Therapeutics INC. | $142.33 | 2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $126.31 | 2024-2025 | Farxiga, Tagrisso |
| Amgen INC. | $98.94 | 2024-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $86.08 | 2024-2025 | |
| Glaxosmithkline, LLC. | $85.78 | 2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $79.53 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.88 | 2024-2025 | Xifaxan |
| Pfizer INC. | $51.65 | 2024-2025 | |
| Almatica Pharma LLC | $51.08 | 2025 | Loreev Xr |
| Lilly USA, LLC | $48.61 | 2024-2025 | Zepbound, Mounjaro, Verzenio |
| Exact Sciences Corporation | $38.22 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $35.43 | 2025 | Trintellix |
| Daiichi Sankyo INC. | $35.03 | 2025 | Datroway |
| Abbvie INC. | $30.82 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.15 | 2025 | Keytruda |
| Verity Pharmaceuticals INC. | $18.57 | 2024 | Tlando |
| Beone Medicines USA, INC. | $17.01 | 2025 | Brukinsa |
| Gilead Sciences, INC. | $16.45 | 2024 | Veklury |
| Janssen Biotech, INC. | $16.26 | 2025 | Rybrevant |
| Geron Corporation | $15.89 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siew Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.